We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Nkarta Inc | NASDAQ:NKTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.37 | -5.87% | 5.93 | 5.50 | 7.44 | 6.50 | 5.90 | 6.50 | 1,951,896 | 05:00:06 |
From Feb 2024 to May 2024
Cowen Annual Health Care ConferenceMarch 6, 20249:10 a.m. ET – industry panel discussion
Leerink Partners Global Biopharma ConferenceMarch 11, 202412:00 p.m. ET – fireside chat
H.C. Wainwright Annual Cell Therapy Virtual ConferenceMarch 26, 20242:00 p.m. ET – fireside chat
A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:Greg MannNkarta, Inc.gmann@nkartatx.com
1 Year Nkarta Chart |
1 Month Nkarta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
